XORTX Therapeutics Inc. (TSXV:XRTX)

Market Cap	5.23M
Revenue (ttm)	n/a
Net Income (ttm)	-4.77M
Shares Out	3.79M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,300
Average Volume	4,148
Open	1.460
Previous Close	1.460
Day's Range	1.380 - 1.460
52-Week Range	1.150 - 4.100
Beta	0.03
RSI	49.62
Earnings Date	May 16, 2025

About XORTX Therapeutics

XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Allen Davidoff
• Employees: 3
• Stock Exchange: TSX Venture Exchange
• Ticker Symbol: XRTX

Financial Performance

Financial numbers in USD